Because HIF2α plays an important role to regulate the expression of SELPLG/PSGL-1 and glycolytic enzymes downstream of mTORC2, it will be interesting to test if this inhibitor is also effective in inhibiting LUSC tumor growth and whether it can improve the current immunotherapy. The gene discussed is EPAS1; the disease is neoplasm.